SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-008697
Filing Date
2022-05-10
Accepted
2022-05-10 06:35:40
Documents
15
Period of Report
2022-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cere-20220510.htm   iXBRL 8-K 56003
2 EX-99.1 cere-ex99_1.htm EX-99.1 262782
3 GRAPHIC img106327088_0.jpg GRAPHIC 3136
4 GRAPHIC img106327088_1.jpg GRAPHIC 3136
  Complete submission text file 0000950170-22-008697.txt   465622

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cere-20220510_lab.xml EX-101.LAB 14020
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cere-20220510.xsd EX-101.SCH 2484
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cere-20220510_pre.xml EX-101.PRE 10288
9 EXTRACTED XBRL INSTANCE DOCUMENT cere-20220510_htm.xml XML 4948
Mailing Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141
Business Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Filer) CIK: 0001805387 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39311 | Film No.: 22907254
SIC: 2834 Pharmaceutical Preparations